The Dutch Kidney Foundation supports talented postdocs and physician researchers through providing personal grants that support different phases of a research career. Kolff grant recipients are foreseen to make important contributions to the field of renal research and to stimulate the application of research results in practice.
The Kolff grants recipients are:
- Raphaël Duivenvoorden, theme Renal disorders
Patients undergoing kidney transplantation are treated with immunosuppressive medication mainly aimed at suppression of the adaptive immune system. These drugs are effective but come at the cost of substantial adverse side effects, such as infections, cancer, and diabetes. In his research he focuses on the development of a new type of treatment aimed at the innate immune system with the aim of preventing acute rejection. For this purpose he will use nanotechnology to deliver medication very specifically to monocytes and macrophages. This has the advantage of efficient delivery of drugs specifically to these cells, while the total amount of medication that enters the body can be minimized, reducing potential side effects.
- Jitske Jansen, theme Renal disorders
Nephrotic syndrome (NS) is characterized by massive proteinuria, hypoalbuminemia and edema, as a result of extensive podocyte foot process effacement. The mainstay of therapy for NS patients is prednisone. NS management is as yet unpredictable, mainly because the molecular mechanisms underlying NS and prednisone treatment are poorly understood. Moreover, prednisone treatment is associated with severe adverse effects. Hence, there is an urgent need to develop more specific therapies to treat NS with less side effects. The aim of her study is to resolve molecular targets regulated by prednisone that are essential for successful podocyte recovery. These results will be instrumental for the development of more specific therapeutic entities to treat NS with less side effects.
Related news items
Ritalin enhances your ability to do tasks by making you more motivated26 March 2020
A new study uncovers how stimulants like Ritalin work in the brain, and it challenges some misconceptions for its recreative use. The collaboration between Radboudumc and Brown University (USA) was published in the journal Science.read more
Dealing with COVID-19 in low- and middle-income countries26 March 2020
RIHS researcher Joost Hopman believes that low-and middle-income countries should intensify their preparedness for a possible COVID-19 outbreak. This was the core message of an opinion article that he wrote at the request of the medical journal JAMA.read more
Physiotherapy is important to the recovery of patients with the coronavirus26 March 2020
Patients who have been infected with the coronavirus and admitted to the hospital for this reason should receive physiotherapy as soon as their condition allows. This is the view expressed by physiotherapists and researchers from the Radboudumc in a set of joint treatment recommendations.read more
Healthcare utilization and regional variation of end-of-life hospital care in Dutch cancer patients26 March 2020
In International Journal of Quality Health Care RIHS researcher Femke Atsma showed high healthcare utilization and medical variation in End of Life care in Cancer patients, which was not associated with GP care or long term care.read more
Study into better protection for healthcare workers against coronavirus infection19 March 2020
Radboudumc and UMC Utrecht will investigate whether health care workers are better protected against the coronavirus after a vaccination against tuberculosis (BCG vaccine). This vaccine does not directly protect against the coronavirus, but provides a boost to the immune system.read more
Differences in the placental disposition of TNF inhibitors uncovered19 March 2020
In Clinical Pharmacology and Therapeutics, researchers from the Depts. of Pharmacology and Toxicology, Obstetrics and Gynecology, and Health Evidence, in collaboration with Sanquin Diagnostic Services, investigated the placental handling of the TNF inhibitors infliximab and etanercept.read more